Bionxt Solutions Secures Key Licensing Deal in Cancer Therapy Market

Bionxt Solutions has announced a major strategic expansion, positioning itself to access a multi-billion dollar segment within the oncology and immunotherapy fields. This move comes as the company seeks to leverage new intellectual property to potentially reinvigorate its share price following a recent period of correction.

On December 1, the company’s management reported a pivotal development: the signing of a Letter of Intent (LOI) to acquire full rights to a novel drug delivery technology. This platform is designed for the sublingual administration—absorption via the mucous membranes under the tongue—of chemotherapy agents and immunosuppressants.

The financial terms of the agreement are structured to be notably investor-friendly. Read more...